Comparison 3. Adverse effects of live attenuated vaccine (intranasal) versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Hospital admission for asthma exacerbation	1		Risk Difference (M‐H, Fixed, 95% CI)	Totals not selected
2 Asthma exacerbations in the month after vaccination	1		Risk Difference (M‐H, Fixed, 95% CI)	Totals not selected
3 Asthma exacerbations in the week following vaccination			Other data	No numeric data
4 Mean FEV1 at 2 to 5 days post vaccination (% predicted)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
5 Number of patients with significant fall in FEV1 (over 12% to 15% or 50 mL) on day 2 to 4	2	65	Risk Difference (M‐H, Fixed, 95% CI)	0.01 [‐0.12, 0.15]
6 Fall in mean FEV1 (L) (day 2 to 4)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
7 Number of puffs of beta2‐agonist per day (in month following vaccination)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
8 Morning peak flow of greater than 30% below baseline at least once in the 4 weeks after vaccination	1		Risk Difference (M‐H, Fixed, 95% CI)	Totals not selected